One of Denmark’s top suppliers of medical cannabis oil products, Stenocare A/S, has revealed a significant regulatory advance for the sector. To make the country’s medical cannabis program permanent, the Danish Parliament has formally passed legislation. This law will take effect on January 1, 2026, ending the existing Pilot Program and replacing it with a long-term, stable framework that benefits both businesses and patients.
In 2018, Denmark launched its medical cannabis pilot program, allowing patients to access cannabis therapies with a prescription. This program initially scheduled its end for December 2025. In November 2024, the Danish Parliament made a formal decision to preserve medical cannabis access indefinitely, providing the industry with much-needed clarity. On April 24, 2025, lawmakers formally enacted the new law, Bill L135.
Denmark: cannabis development for patients and industry
Patients who depend on these therapies are celebrating the permanent legalization of medical cannabis as a major breakthrough. Positive results from medical cannabis have been reported by numerous individuals, especially when used as an alternative to traditional medicines. Patients won’t have to worry about losing access to the treatments they depend on thanks to this legislation.
Thomas Skovlund Schnegelsberg, CEO of Stenocare, called the ruling a “day of celebration,” highlighting the triumph it signifies for the organization and its patients.
“A clear and positive decision to permanently allow treatment with medical cannabis in Denmark has replaced uncertainty,” he stated. “The result is win-win.”
Why is the new cannabis law a positive thing?
The revised law adds a number of significant improvements aimed at helping people and healthcare professionals. The Danish Medicines Agency has introduced modified medical recommendations to give doctors more confidence when prescribing medical cannabis. This change represents one of the most significant developments.
The Danish Patient Safety Authority will reexamine the standards for determining cannabis treatment-related limits. It will potentially lead to fewer restrictions for patients. The current 50% medical cannabis product subsidy will remain in place, ensuring ongoing affordability.
When taken as a whole, these modifications should improve patient safety, increase access, and encourage more uniform, lawful treatment alternatives nationwide.
Prospect for Stenocare
Since the Pilot Program’s beginning, Stenocare has taken an active role in the creation of the medical cannabis framework in Denmark. Stenocare has established itself as a major player and thought leader in the Danish market by collaborating closely with legislators and health authorities. Now that permanent law has been established, Stenocare is in a strong position to thrive over the long run. The company feels confident enough to keep investing in supply chain development and innovation for its medicinal cannabis oil products because of the regulatory clarity. What is more, Stenocare has been contuously developing its products.
Denmark is now a leading country in Europe. It embraces controlled, prescription-based access to medical cannabis. In addition to helping patients at home, this action enhances the country’s position as a model for other EU nations thinking about implementing such reforms.
The enactment of Bill L135 ushers in a new era for medical cannabis in Denmark, marked by safety, encouragement, and enormous promise for improving patient outcomes and advancing the sector.